Skip to Content
About Abbott
Contact
United States | eng
Country Language
CARDIOVASCULAR
United States | eng
Country Language

MultiPoint™ Pacing

Gallant™ CRT-Ds, Quadra Allure MP™ CRT-Ps & Quartet™ Quadripolar LV Leads

gradient banner

Unlock the MORE-CRT MPP Potential with Abbott's CRT Portfolio

The MORE-CRT MPP trial is one of the largest prospective, multicenter, randomized controlled trials designed to assess clinical response in patients indicated to cardiac resynchronization therapy (CRT).1

The results from the secondary analysis show that MultiPoint Pacing (MPP), in patients who do not respond to BiVP, is associated with clinically relevant and statistically significant reduction of hard endpoints, such as heart failure (HF) hospitalizations or all-cause mortality.2

Late-Breaking Evidence: Cardiac Implantable Electrical Devices Session, EHRA 2025

Learn more about the latest insights from the secondary analysis of MORE-CRT MPP data.

Download clinical intel

 

Significant reduction of all-cause mortality and HF hospitalizations in CRT non-responders1

The MORE-CRT randomized global study proved significant reduction of all-cause mortality and HF hospitalizations in CRT non-responders.1

 Over time, Heart Failure (HF) hospitalizations or death was significantly lower in MPP patients compared to BiVP patients with a relative risk reduction of 37%.

Furthermore, results from this study showed that the risk of HF hospitalizations or any-cause death was improved in the whole population as well as patient subgroups such as:

  • Ischemic cardiomyopathy
  • Very wide QRS (≥ 160 ms)
  • Long interventricular delay (>105 ms)

 

View the study

References

1. Leclercq C, Burri H, Delnoy PP, Rinaldi CA, Sperzel J, Calò L et al. Cardiac resynchronization therapy non-responder to responder conversion rate in the MORE-CRT MPP trial. Europace 2023;25:euad294.

2. Leclercq C, Burri H, Calò L, Rinaldi CA, Sperzel J, Thibault B et al. Multipoint pacing is associated with reduction of heart failure hospitalizations or death in patients who do not respond to cardiac resynchronization therapy: results of the MORE-CRT MPP randomized trial, EP Europace, Volume 27, Issue 6, June 2025, euaf070.

MAT-2512138 v1.0

Stay Informed

Sign up to hear about our technology, education opportunities, and more.

Join Our Email List

Read the Latest Blog Article

Stay up to date with recent news, product highlights, and case studies.

Visit the Abbott CRM Blog
POLICIES & ADVISORIES
HEALTHCARE PROFESSIONALS
PATIENTS & CAREGIVERS
abbott logo

CAUTION: These products are intended for use by or under the direction of a physician. Prior to use, reference the Instructions for Use, inside the product carton (when available) or online for more detailed information on Indications, Contraindications, Warnings, Precautions and Adverse Events.

Illustrations are artist's representations only and should not be considered as engineering drawings or photographs.

Unless otherwise specified, all product names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company. ™ Indicates a trademark of the Abbott group of companies. ‡ Indicates a third party trademark, which is property of its respective owner.

© 2025 Abbott. All Rights Reserved.

MAT-1900882 v15.0